Text size The Food and Drug Administration on Tuesday rejected Gilead Science’s application for a will-be blockbuster arthritis medicine, blind investors. One analyst called the development a ‘near-worst-case scenario’ and a ‘shock’. Dreamstime The Food and Drug Administration’s decision to deny Gilead Science’s application for a wild medicine for blockbuster …
Read More »Potential Gilead blockbusters rejected by FDA. Why that’s the ‘Near-Worst-Case Scenario’ for Gilead Stock.
